You just read:

Nektar Therapeutics Presents Biomarker and Clinical Data from PIVOT-02 Phase 2 Study of Bempegaldesleukin with Nivolumab at 2019 ASCO Annual Meeting

News provided by

Nektar Therapeutics

Jun 01, 2019, 09:00 ET